Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients.
van der Putten K, Jie KE, van den Broek D, Kraaijenhagen RJ, Laarakkers C, Swinkels DW, Braam B, Gaillard CA. van der Putten K, et al. Among authors: van den broek d. Eur J Heart Fail. 2010 Sep;12(9):943-50. doi: 10.1093/eurjhf/hfq099. Epub 2010 Jul 3. Eur J Heart Fail. 2010. PMID: 20601671 Free article. Clinical Trial.
Determinants of red cell distribution width (RDW) in cardiorenal patients: RDW is not related to erythropoietin resistance.
Emans ME, van der Putten K, van Rooijen KL, Kraaijenhagen RJ, Swinkels D, van Solinge WW, Cramer MJ, Doevendans PA, Braam B, Gaillard CA. Emans ME, et al. Among authors: van rooijen kl, van der putten k, van solinge ww. J Card Fail. 2011 Aug;17(8):626-33. doi: 10.1016/j.cardfail.2011.04.009. Epub 2011 May 28. J Card Fail. 2011. PMID: 21807323 Free article. Clinical Trial.
Short-term erythropoietin treatment does not substantially modulate monocyte transcriptomes of patients with combined heart and renal failure.
Jie KE, van der Putten K, Wesseling S, Joles JA, Bergevoet MW, Pepers-de Kort F, Doevendans PA, Yasui Y, Liu Q, Verhaar MC, Gaillard CA, Braam B. Jie KE, et al. Among authors: van der putten k. PLoS One. 2012;7(9):e41339. doi: 10.1371/journal.pone.0041339. Epub 2012 Sep 5. PLoS One. 2012. PMID: 22957013 Free PMC article. Clinical Trial.
Neutrophil gelatinase-associated lipocalin (NGAL) in chronic cardiorenal failure is correlated with endogenous erythropoietin levels and decreases in response to low-dose erythropoietin treatment.
Emans ME, Braam B, Diepenbroek A, van der Putten K, Cramer MJ, Wielders JP, Swinkels DW, Doevendans PA, Gaillard CA. Emans ME, et al. Among authors: van der putten k. Kidney Blood Press Res. 2012;36(1):344-54. doi: 10.1159/000343392. Epub 2012 Dec 12. Kidney Blood Press Res. 2012. PMID: 23235391 Free article. Clinical Trial.
Relation between Red Cell Distribution Width and Fibroblast Growth Factor 23 Cleaving in Patients with Chronic Kidney Disease and Heart Failure.
van Breda F, Emans ME, van der Putten K, Braam B, van Ittersum FJ, Kraaijenhagen RJ, de Borst MH, Vervloet M, Gaillard CA. van Breda F, et al. Among authors: van der putten k. PLoS One. 2015 Jun 16;10(6):e0128994. doi: 10.1371/journal.pone.0128994. eCollection 2015. PLoS One. 2015. PMID: 26079688 Free PMC article. Clinical Trial.
Epoetin Beta and C-Terminal Fibroblast Growth Factor 23 in Patients With Chronic Heart Failure and Chronic Kidney Disease.
Eisenga MF, Emans ME, van der Putten K, Cramer MJ, Diepenbroek A, Velthuis BK, Doevendans PA, Verhaar MC, Joles JA, Bakker SJL, Nolte IM, Braam B, Gaillard CAJM. Eisenga MF, et al. Among authors: van der putten k. J Am Heart Assoc. 2019 Aug 20;8(16):e011130. doi: 10.1161/JAHA.118.011130. Epub 2019 Aug 17. J Am Heart Assoc. 2019. PMID: 31423921 Free PMC article. Clinical Trial.
25 results